Currently, the most prevalent immune checkpoint receptors that have been used to manipulate the immune system for cancer immunotherapy are PD1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); both are T-cell surface receptors. This evidence concerns the gene CTLA4 and cancer.